COMPANY

Geron

HQ: Parsippany, NJ source · geron.com ↗ · West Coast

Geron is a hematology biopharmaceutical company. From company website Source · Oct 13, 2026

Keywords: hematology biopharmaceutical Myelofibrosis Multiple Myeloma Myelodysplastic Syndromes Primary Myelofibrosis Secondary Myelofibrosis Myeloid Malignancies Essential Thrombocythemia Polycythemia Vera Non-small Cell Lung Cancer Locally Recurrent or Metastatic Breast Cancer Lung Cancer Chronic Lymphoproliferative Diseases Breast Cancer Solid Tumor Malignancies Imetelstat Imetelstat Sodium (GRN163L) GRN163L

Location: Parsippany, NJ · source · Oct 15, 2026

Profile checked Oct 10, 2026

$375.0MRaised (2 yrs)16Trials (company is sponsor)

Timeline

Nov 7, 2024 Raise Private placement: $375M (up to, as announced), announced Nov 7, 2024. Source: SEC filing. source ↗
May 4, 2022 Trial start Phase 1: A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis source ↗
Apr 12, 2021 Trial start Phase 3: A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment source ↗
Jan 12, 2016 Trial start Phase 2/Phase 3: Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) source ↗
Aug 28, 2015 Trial start Phase 2: Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor source ↗
Oct 29, 2012 Trial start Phase 2: Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis source ↗
2010-12 Trial start Phase 2: Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera source ↗
2010-11 Trial start Phase 2: Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma source ↗
2010-11 Trial start Phase 2: Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer source ↗
2010-05 Trial start Phase 2: Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC) source ↗
2008-07 Trial start Phase 1: A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer source ↗
2008-07 Trial start Phase 1: Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma source ↗
2007-11 Trial start Phase 1: Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma source ↗
2007-07 Trial start Phase 1: Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer source ↗
2006-03 Trial start Phase 1: Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies source ↗
2005-07 Trial start Phase 1: Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) source ↗

Upcoming milestones

2027-02 (ESTIMATED) · Phase 1 · A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis · NCT05371964
Jun 30, 2028 (ESTIMATED) · Phase 3 · A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment · NCT04576156

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $375.0M. Last 2 years.

Nov 7, 2024 Private placement: $375M (up to, as announced), announced Nov 7, 2024. Source: SEC filing. source ↗

Clinical trials (lead sponsor) 16

Record	Title	Phase	Status	Start	Primary completion
NCT05371964	A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis	Phase 1	Active, not recruiting	May 4, 2022	2027-02 (estimated)
NCT02598661	Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)	Phase 2/Phase 3	Active, not recruiting	Jan 12, 2016	Oct 13, 2023 (actual)
NCT04576156	A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment	Phase 3	Active, not recruiting	Apr 12, 2021	Jun 30, 2028 (estimated)
NCT01242930	Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma	Phase 2	Completed	2010-11	2014-11 (actual)
NCT05937568	Expanded Access for Treatment With Imetelstat	Not listed	Approved for marketing	Not listed	Not listed
NCT01731951	Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis	Phase 2	Completed	Oct 29, 2012	May 24, 2018 (actual)
NCT02426086	Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor	Phase 2	Completed	Aug 28, 2015	Apr 26, 2018 (actual)
NCT01243073	Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera	Phase 2	Completed	2010-12	2013-10 (actual)
NCT01137968	Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)	Phase 2	Completed	2010-05	2013-09 (actual)
NCT01256762	Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer	Phase 2	Completed	2010-11	2012-10 (actual)
NCT00510445	Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer	Phase 1	Completed	2007-07	2011-04 (actual)
NCT00594126	Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma	Phase 1	Completed	2007-11	2011-07 (actual)
NCT00124189	Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)	Phase 1	Completed	2005-07	2013-03 (actual)
NCT00732056	A Study of GRN163L With Paclitaxel and Bevacizumab to Treat Patients With Locally Recurrent Or Metastatic Breast Cancer	Phase 1	Completed	2008-07	2011-09 (actual)
NCT00718601	Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma	Phase 1	Completed	2008-07	2011-10 (actual)
NCT00310895	Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies	Phase 1	Completed	2006-03	2013-03 (actual)